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Abstract
Coronavirus disease 2019 (COVID-19) is a respiratory illness that started and rapidly became the pandemic of the century, as the number
of people infected with it globally exceeded 253.4 million. Since the beginning of the pandemic of COVID-19, over two years have
passed. During this hard period, several defies have been coped by the scientific society to know this novel disease, evaluate it, and treat
affected patients. All these efforts are done to push back the spread of the virus. This article provides a comprehensive review to learn
about the COVID-19 virus and its entry mechanism, its main repercussions on many organs and tissues of the body, identify its symptoms
in the short and long terms, in addition to recognize the role of diagnosis imaging in COVID-19. Principally, the quick evolution of active
vaccines act an exceptional accomplishment where leaded to decrease rate of death worldwide. However, some hurdels still have to be
overcome. Many proof referrers that infection with CoV-19 causes neurological dis function in a substantial ratio of influenced patients,
where these symptoms appear severely during the infection and still less is known about the potential long term consequences for the
brain, where Loss of smell is a neurological sign and rudimentary symptom of COVID-19. Hence, we review the causes of olfactory bulb
dysfunction and Anosmia associated with COVID-19, the latest appropriate therapeutic strategies for the COVID-19 treatment (e.g., the
ACE2 strategy and the Ang II receptor), and the tests through the follow-up phases. Additionally, we discuss the long-term complications
of the virus and thus the possibility of improving therapeutic strategies. Moreover, the main steps of artificial intelligence that have been
used to foretell and early diagnose COVID-19 are presented, where Artificial intelligence, especially machine learning is emerging as
an effective approach for diagnostic image analysis with performance in the discriminate diagnosis of injuries of COVID-19 on multiple
organs, comparable to that of human practitioners. The followed methodology to prepare the current survey is to search the related work
concerning the mentioned topic from different journals, such as Springer, Wiley, and Elsevier. Additionally, different studies have been
compared, the results are collected and then reported as shown. The articles are selected based on the year (i.e., the last three years).
Also, different keywords were checked (e.g., COVID-19, COVID-19 Treatment, COVID-19 Symptoms, and COVID-19 and Anosmia).
Keywords: artificial intelligence for COVID-19; COVID-19; COVID-19 treatment; COVID-19 symptoms; COVID-19 and anosmia;
imaging in COVID-19

1. Introduction
A cluster of fatal pneumonia cases was reported in December 2019. The infection spread rapidly as visitors transmitted the infection to several countries, evoking memories
of past pneumonia outbreaks such as Severe Acute Respiratory Syndrome (SARS) and the Middle East Respiratory Syndrome (MERS). Patients with severe COVID-19
have emerged as a high-risk cohort for invasive fungal infections (IFIs) [1]. Shortness of breath began to spread
among patients whose pathological causes were unknown

and it was treated as influenza infection at that time [2].
Based on clinical criteria, serologically, and molecular information, the new infection was termed coronavirus disease 2019 (COVID-19) [3]. An increased incidences of cardiovascular has been recognized in those with COVID-19
[4]. Therefore, in the case of patients with cardiovascular disease infected with the COVID-19 virus, it may lead
to inflammation of the heart muscle or cardiac arrhythmias
and may even lead to death [5]. COVID-19 injuries did not
affect the respiratory system only, but also damaged most
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of the body’s systems in the short and long term, such as
the digestive and nervous systems. For COVID-19, there is
an elevated rate of cerebral outcomes, especially Anosmia
caused by the effect of COVID-19 on the olfactory bulb.
Loss of smell is an early sign of infection, which can take
weeks, months, or more (i.e., up to a year to recover from)
[6]. The number of infections and deaths from COVID-19
has increased worldwide. However, the number of people
healing from COVID-19 infection has increased. Statistically, for November 13, 2021, the number of COVID-19
cases worldwide has reached nearly 253.4 million, the total
number of deaths worldwide is about 5.1 million, and the
total number of people recovered worldwide is about 229.2
million. The total number of COVID-19 patients per million of the world’s population is about 32,506, while the total number of COVID-19 deaths per million of the world’s
population is about 655.3 [7].
1.1 Survey Objectives and Contributions
The main objective of the current survey is to review
to learn about the Role of Imaging and AI in the Evaluation of COVID-19 Infection. This is done by gathering
knowledge about COVID-19 virus, its main repercussions
on many organs and tissues of the body, to identify the
symptoms of COVID-19 in the short and long term, as well
as the post-acute consequences of COVID-19 infection on
many organs of the body. Additionally, this work reviews
the causes of dysfunction and loss of sense of smell associated with COVID-19, the latest appropriate therapeutic
strategies to combat COVID-19, and methods of follow-up
for those recovering from COVID-19. It discusses the longterm complications of the virus and thus the possibility of
improving therapeutic strategies. Also, the main steps of
artificial intelligence that are used to predict and early diagnose COVID-19 are presented. The contributions can be
summarized in points as follows:
– Reporting the COVID-19 infection and its entry
mechanism.
– Presenting the early common impacts and symptoms
of COVID-19 in the short-term and discussing the impacts
and symptoms of COVID-19 in the long-term.
– Discussing the impacts of COVID-19 on the olfactory bulb which lead to Anosmia.
– Presenting the diagnoses imaging In COVID-19 and
its outcomes.
– Presenting the treatment strategies and follow-ups.
Getting familiar with the COVID-19 AI systems’
internals and reviewing state-of-the-art published articles
concerning the different AI-based system phases.
1.2 Paper Organization
The current survey is organized as follows: the following section presents the COVID-19 infection and its Entry
Mechanism. Section 2 discusses early common impacts and
symptoms of COVID-19 on both short-term and long-term.
2

It discusses the impacts of COVID-19 on the olfactory Bulb
which can lead to Anosmia. Additionally, the diagnoses
imaging in COVID-19 and its outcomes is presented. Section 3 presents the treatment strategies and follow-up approaches. Section 4 concerns the AI-based systems related
to COVID-19 and their phases, in addition to comparing
different state-of-the-art published studies. The limitations
of the current survey are presented in Section 5. The survey
is concluded and the future work is discussed in Section 6.

2. COVID-19 Infection and COVID-19 Virus
Entry Mechanism
The current section briefly provides a definition of
COVID-19, the type of viruses to which COVID-19 belongs, and the similarities of it with previous coronaviruses.
SARS-CoV-2 acts as the 7th member of the Coronaviridae family recognized to infect humans. Its analogs contain four families of weak effects (229E, OC43, NL63,
and HKU1), in addition, to two other B-coronaviruses
that caused the prior spread of acute and potentially lethal
respiratory tract infections—SARS-CoV and the Middle
East respiratory syndrome- Coronavirus (MERS-CoV) [8].
Coronavirinae (i.e., coronavirus) is a subfamily of viruses
that infect mammals, often presenting as respiratory or enteric infections. Coronaviruses are large, positive, singlestrand RNA viruses. Their morphology can be described
as spherical virions with a central shell and surface protrusions like the solar corona as shown in Fig. 1 [9]. SARSCoV-2 is closely related to the SARS-CoV virus [9]. It
also participates in the same cellular receptor as SARS-CoV
which is the angiotensin-converting enzyme 2 (ACE2) receptor [10]. ACE2 receptors are reinforced in alveolar epithelial type II cells of lung tissues [11], as well as extrapulmonary tissues such as the heart, endothelium, renal, and
intestines [12,13], which might play a role in the multiorgan impacts of COVID-19. SARS-CoV-2 has the typical
characteristics of coronaviruses. It contains a genetic sequence of 79% identical to SARS-CoV and 50% related to
the MERS-coronavirus (MERS-CoV) [14,15]. The severity of COVID-19 infection ranges from very mild to severe
as the levels of infection severity depend on the individual’s
immune system, age, and comorbidities [16].
2.1 COVID-19 Virus Entry Mechanism
Entry of virus into host cells is a prerequisite for coronavirus infection. Spike protein (S protein) interacts with
the receptors of host cells, hence, it causes the fusion of the
membranes of the cellular and viral. Via biological analysis, the S protein of both COVID-19 and SARS-CoV is similar. To infect epithelial cells, the S protein interacts with
the ACE2 receptor on the surface of host cells [17]. So, the
ACE2 molecule is the primary molecule of COVID-19 infection [17]. ACE2 is expressed in the human respiratory
system as well as in arterial endothelial and smooth muscle
cells. It has a crucial and major role in the COVID-19 in-
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Fig. 1. The Coronavirus Morphology.

fection [13]. Transmission of infection occurs through three
possibilities: transmission of respiratory droplets by coughing or sneezing, aerosols, usually during clinical transactions to produce aerosols, and mucosal link with fomites
[18,19].
2.2 Early Common Impacts and Symptoms of COVID-19
on Short-Term
The current subsection presents the main clinical
symptoms of COVID-19 infection in the short term. Pneumonia is the early medical diagnosis of the SARS-CoV-2
[16]. The clinical symptoms include fever, cough, nasal
congestion, and fatigue, in addition to other signs such as
shortness of breath [9]. The most common signs of viral
pneumonia are low oxygen levels and blood gas aberrations. Also, ground-glass opacity, irregular fusion, alveolar
exudation, and interlobular involvement are the most common signs of pneumonia in medical images [20]. Francone
et al. [21] investigated the short-term impact of COVID19. Their study used computed tomography (CT) to determine its predictive ability to patient outcomes. Then,
a correlation between a semi-quantitative result of pulmonary embroilment in pneumonia resulting from COVID19 with clinical progression and laboratory outcomes was
computed. The study included 130 COVID-19 patients, and
all of them experienced an RT-PCR test to confirm their infection. The most common clinical appearance was fever,
coughing, dyspnea, and high temperature. The raised levels of CRP existed in 86% patients and raised levels of

D-dimer existed in 87.7% patients. Reduced lymphocyte
number was observed in 61.5% patients, reduced O2 saturation was observed in 40.1%, and reduced PaO2/FiO2
ratio was observed in 66.2% patients. According to Chinese CDC clinical results [22], 60.8% were categorized as
mild, 32.3% as severe, and 6.9% as serious. Concerning
the beginning time of symptoms, cases were classified as
either early (i.e., 0–7 days) or late clinical manifestations
(i.e., >7 days) [23]. The study also proved the following:
the early stage (7 days after symptoms appear) of COVID19 infection is characterized by the spread of ground-glass
opacity. The late stage of infection was characterized by a
crazy-paving pattern, consolidation, and fibrosis. In severe
COVID-19 cases, CT scans give very good and clear results compared to simple COVID-19 cases. In late-stage
COVID-19 infection, the CT findings correlated with ddimer and C-reactive protein (CRP) levels [16]. Neurological manifestations range from minor symptoms such as loss
of smell, dizziness, and headache to severe symptoms such
as seizures and encephalitis [24]. Fig. 2 summarizes the
COVID-19 symptoms on short-term. Although anosmia
belongs to the early symptoms of infection in short term,
recovery from it may extend for months or more, and therefore it also falls within the long-term effects of COVID-19.
2.3 Common Impacts and Symptoms of COVID-19 on
Long-Term
The COVID-19 pandemic presents a direct unprecedented and still identifies as a threat, especially to health
3
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Fig. 2. Short-term symptoms development summarization.

care systems. Worldwide, the total number of infected patients skipped the health care system capacities, especially
the patients that needing helped ventilation. During the
severe stage of COVID-19 infection, nearly 36% of cases
develop neurological symptoms, 25% of which can be attributed to the immediate involvement of the central nervous system. For example, the major symptoms contain
headache, dizziness, seizure, and impaired consciousness
[25]. Among patients presenting with neurological symptoms, there may be cases with (or without) pre-existing neurological disorders [26]. Affected people displayed excitation, chaos, and corticospinal tract signs, e.g., enhanced tendon reflexes and clonus during intensive care units, while in
mild to intermediate disease cases about 85.6% of patients
reported olfactory dysfunctions and about 88.0% of patients
reported gustatory dysfunctions. Interestingly, around 11%
of patients reported anosmia occurred first before any other
symptoms [27].
Additionally, COVID-19 can cause alterations in coagulation, especially inflammation-produced disseminated
intravascular coagulation (DIC). DIC can lead to cerebrovascular ischemia including the little patients, jointly
with endothelial dysfunction, where several of them suffer
from big vessel ischemic stroke [28]. About 5.7% of the
acute cases experienced ischemic stroke [25] or had preexisting vascular hazard agents particularly in the old person, in whom ischemic stroke rather occurred as a delayed
complication [29,30]. Further, sub-acute symptoms that occurred 3–10 days after the evolution of COVID-19 symptoms such as Guillain-Barre´ syndrome [31] and MillerFisher syndrome [32]. The adverse effect of COVID19 on the central nervous system is expressed by several possible mechanisms such as direct viral encephalitis, systemic inflammation, dysfunction of peripheral organs (i.e., liver, kidney, lung), and cerebrovascular alterations. However, many cases may show a mixture of these
neurological appearances [26]. In addition to neurological damages, acute renal injury, hyperglycemia, thrombotic
4

problems, cardiac dysfunction, arrhythmia, acute coronary syndromes, and hepatocyte injury are other symptoms of COVID-19 [33,34]. Persons who survive COVID19 may be at risk of developing long-term neurological
consequences due to aggravating a pre-existing neurological disorder or by emerging a new disorder [26]. The
presence of COVID-19 infection is linked with an acute
immune response and increased levels of systemic cytokines. Accordingly, this innate immune response has
been exploited to predict infection severity and mortalities rate [35]. Cytokines and inflammatory mediators
that have raised levels in response to COVID-19 infection include: interleukin-1β, interleukin-2, interleukin2 receptor, interleukin-4, interleukin-10, interleukin-18,
interferon-γ, C-reactive protein, granulocyte colony stimulating factor, CXCL10, monocyte chemoattractant protein
1, macrophage inflammatory protein 1-α, and tumor necrosis factor-α [36,37]. In addition to this, T-cell depletion in
many COVID-19 patients and reduced lymphocyte number
are considered signs [38,39]. In parallel, acute respiratory
distress syndrome (ARDS) is the most prevalent clinical
presentation among COVID-19 patients [40], as lung injury
models in mice and some ARDS patients confirmed the role
of NLRP3 in the pathogenesis of infection with acute respiratory distress syndrome and negative results [41,42]. Also,
the inflammatory activity of NLRP3 is stimulated by the
coronavirus ORF3a protein [43]. In addition, ventilationproduced hypercapnia has been experimentally shown to
lead to cognitive impairment in a NLRP3 inflammasomeinterleukin-1β-dependent manner [44]. The long-term impact of COVID-19 on other organs such as:
– Blood: The number of patients who experienced
thromboembpost-acute COVID-19 is less than 5%, and the
period for COVID-19 hyperinflammation is unknown. Anticoagulants and low molecular weight heparin are considered long-term anticoagulant prophylaxis in persons at risk
of persistently elevated d-dimer levels, loss of motility, or
high-risk comorbidities [45].
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Fig. 3. Long-term symptoms development summarization.

– Kidneys: Most patients recover from acute kidney injury during the follow-up interval, however, during 6 months of follow-up, a decrease in the estimated
glomerular filtration rate (eGFR) was reported. COVID19-associated nephropathy (COVAN) is most commonly
found among people of African descent, among those who
suffer from chronic problems in kidney function and recover from COVID-19. Early follow-up for these patients
in the clinics specializing in acute renal impairment is necessary [45].
– Endocrine: Endocrine sequelae include new or
worsening control of diabetes mellitus and moderate thyroiditis. In cases of newly diagnosed diabetes, in the absence of conventional risk factors for type 2 diabetes, laboratory tests for hypothalamic-pituitary-adrenal axis suppression or hyperthyroidism should be performed and the
patients should be referred to an endocrinologist [45].
– Hepatobiliary and Gastrointestinal: Even after
a negative result on nasopharyngeal swab examination, a
prolonged viral signal may be detected in feces following
COVID-19 infection. By fertilizing opportunistic organisms and reducing beneficial compensation, COVID-19 can
change the gut microbiome [45].
– Dermatologic: Hair loss is a common symptom,
with around 20% of PASC patients reporting it [45].
– Multisystem Inflammatory Syndrome in Children (MIS-C): MIS-C is also known as a pediatric multisystem inflammatory syndrome. According to the WHO,
fever, severe inflammatory signs, and multiple organ dysfunction are most common among people under the age of
21. Children’s injuries occur in those whose ages are under
7 years. Cardiovascular and neurological disease, fever, abdominal pain, vomiting, diarrhea, and rash are the clinical

manifestations of MIS-C [45].
COVID-19 infection often lasts between one to four
weeks [46]. However, a subset of patients who become
infected with SARS-CoV-2 develop a variety of chronic
symptoms that last for months [46,47]. Nearly 30% of
COVID-19 patients, who were followed up for 9 months,
had chronic symptoms. Post-acute sequelae of COVID-19
(PASC) is the most appropriate term to describe the issues
faced by these patients [48]. Fig. 3 summarizes the COVID19 symptoms on long-term.
2.4 Impacts of COVID-19 on Olfactory Bulb which Lead
to Anosmia
The current subsection presents the relationship between COVID-19 and partial (or complete) Anosmia. The
olfactory nerve is described as being tiny in size and can
only be seen by MRI of the base of the skull [49]. The olfactory bulbs are located over the cerebral plate, below the
olfactory sulcus, and inside the anterior cranial fossa [50] as
shown in Fig. 4. The morphology of the olfactory bulb was
considered normal if it appeared in an oval shape or J shape
and abnormal if it appeared in an oblong or atrophic appearance [51]. Reverse neurological signs have been recognized
in the configuration of hyposmia, anosmia, headache, dysgeusia, disgust, puke, commotion, raving, and wreaked realization [52–56].
Coronaviruses are mostly neurotropic [57], where the
particles of COVID-19 were revealed in human brain neurons [12]. Therefore, CoV-19 can arrive in the CNS, hence,
causing neuronal damage. There are three suppositions of
CoV-19 entrance into the CNS, namely, intranasal inoculation with diffusion by the olfactory bulb and nerves to
the brainstem, transsynaptic diffusion from neuron to neuron by endocytosis (exocytosis), or hematogenous diffusion
5

scanned. This study examined 19-year-old female suffering from persistent loss of smell as a result of COVID-19
infection. The patient underwent RT-PCR to confirm the infection and the result was positive. After recovering from
the infection, she still suffers from anosmia. An MRI was
performed after two months to find out that atrophy in the
olfactory bulb is the reason for the continued loss of smell.
By comparing the result of the MRI that the patient had previously done for other reasons and the current imaging due
to infection with COVID-19, it was proved that there was
a difference in the sizes of the olfactory bulbs. The size of
the olfactory bulb 3 years before the loss of smell due to
COVID-19 was 47.46 mm3 and 49.5 mm3 , The size after
the loss of smell was 35.51 mm3 and 29.96 mm3 while the
minimum size of the olfactory bulb for women under the
age of 45 is 54 mm3 .
2.5 Diagnosis Imaging in COVID-19 and Its Outcomes

Fig. 4. The location of the olfactory bulbs in a DTI image for
a COVID-19 patient.

by affected monocytes and crossing the blood-brain barrier [58]. There are three mechanisms for Pathophysiology of CNS from COVID-19, either immediate viral entrance into the brain, inverse immune response, or respiratory strain [59]. Recently, the empirical proof showed that
a human CoV progeny and HCoV OC43 can be transported
to the olfactory bulb through the nasal cavity, then diffuse
to the piriform cortex, and brainstem by the negative outbreak and axonal transition [60,61]. There are a large number of viruses that interact with the receptors of the nasal
mucosa, resulting in inflammation-causing the dysfunction
[62]. The upper respiratory tract does not have distinct
symptoms that enable the doctors to differentiate with certainty between infection with COVID-19 and other viruses.
As the mechanism of viral infection for most viruses is similar, the virus enters through the epithelium of the respiratory tract and interacts with the ACE2 receptors [63]. The
interaction may occur directly or indirectly, thus, the olfactory neurons may be affected and lead to the emergence of
neurological symptoms [64].
Strauss et al. [50] proved that the MRI is a reliable
medical imaging method to confirm olfactory system injuries in those who suffer from COVID-19 with the presence of neurological symptoms. The diseases of the olfactory bulb in people with COVID-19 are a defect or anomalies in the olfactory bulb signal. Chiu et al. [49] have noted
that the loss or decreased sense of smell is one of the symptoms of COVID-19, as 60% of people with COVID suffered
from it. However, the olfactory nerve was not primarily
6

Medical imaging techniques play a major part in diagnosing the infection with COVID-19, primely, concerning
the first symptoms of pulmonary disease and the tissue allocation of the angiotensin-converting enzyme 2 (ACE 2)
receptor. The non-sensitivity of RT-PCR scans for positive
diagnosis is the main motive for resorting to medical imaging approaches.
Quantitative imaging including the “radiomics and artificial intelligence” introduced interesting findings in pulmonary disease detection in the short- and middle-term and
foretell long-lasting fibrotic alters [65,66]. In extension to
the different pulmonary symptoms, COVID-19 is a systemic disease with broad impacts on matures and youths
that can be evaluated using imaging [67–70]. For example, Gastrointestinal symptoms, colitis signs at computed
tomography such as bowel wall thickening [68–71], olfactory bulb abnormality in MR and induced anosmia [51,69].
Additionally, myocarditis-similar markers such as myocardial edema or delayed gadolinium enhancement in children who are suffering from multisystem inflammatory syndrome (MIS-C) due to COVID-19 [70,72], all of these
symptoms indicate the presence of COVID-19 infection.
These symptoms can be detected through an appropriate
medical imaging model of each organ or tissue. Such a
broad group of symptoms may occur and continue to the
post-COVID syndrome that may last for more than a year
[73]. Also, patients may suffer from cardiovascular, enduring pulmonary, endocrine, gastrointestinal, hematologic,
psychiatric signs, and neurological [74]. For example, neuroinflammatory mechanisms in addition to the influences of
microvascular damages revealed at MR are responsible for
severe and continuous neurological symptoms [75,76].
Several studies have demonstrated COVID-19 has significant implications for the Olfactory bulb using the results of CT and MRI that many patients with anosmia have
undergone. Where the results of some tests showed that
COVID-19 causes an olfactory dysfunction due to the pres-

ence of a change in the shape and size of the olfactory
bulb in some people with anosmia caused by COVID-19.
There are reports of neurological symptoms in patients with
COVID-19, denoted to the neurotropic nature of the virus
[52]. Animal surveys displayed that the viral permeation
occurs in the olfactory bulb and then spread to the subcortical area and cortical area. In the premier survey from
Wuhan, 5.1% and 5.6% of 214 COVID-19 cases had suffered from anosmia and loss of taste, respectively [25].
According to an American study [77], the loss of the
sense of smell is strong evidence of infection with COVID19. A case with a sudden loss of the sense of smell underwent MRI and CT on the nasal sinuses. The result was
a normal appearance of the olfactory bulb and olfactory
tracts and the presence of bilateral inflammation in the olfactory cleft [78]. Tissues of nasal from patients with postviral anosmia show severe purulence, missing or fewer cilia
on surviving receptor cells [79]. However, the causes of
COVID-19 infection are still unknown [80]. A sample of
the olfactory epithelium could be used as a source of tissue for primary viral identification to reduce the number
of incorrect-negative examination findings [81]. There are
two options: (1) a post-viral anosmia syndrome with direct infection and inflammation of the olfactory mucosa and
neurodegeneration of the olfactory sensory neurons or (2)
an upper respiratory infection with some smell loss as a
result of nasal inflammation, mucosal edema, and impediment of the flow of air into the olfactory cleft. Signs of illness development include injury to the peripheral nerve system, as well as its malfunction, such as anosmia or hyposmia [82,83]. A major multicenter European survey reported
that 85.6% and 88% of 417 COVID-19 patients experienced
olfactory weakness and taste dysfunction, respectively [27].
However, a modern survey from Spain notarized anosmia
in 4.9% and loss of taste in 6.2% of 841 patients [84]. In a
survey after death, MRI of non-survivors demonstrated the
occurrence of olfactory bulb asymmetry and atrophy in 4 of
19 COVID-19 cases [85]. In a case study with screening 4
days after the beginning of anosmia, signal changes of the
olfactory bulb in MRI along with a signal increase in the
gyrus rectus and bilateral atrophy were documented [69].
The nasal sinuses underwent CT and the olfactory
nerves underwent MRI [51]. The measurements were done
based on imaging findings to assess the nasal sinuses and
opacity of the olfactory clefts. They were:
– Paranasal Sinus CT: Based on CT of the sinuses,
the ventilation pattern of the olfactory cleft was classified
as normal, partial, or whole opacity [51].
– Olfactory Cleft Opacification: The olfactory clefts
were lined by an olfactory epithelium that contained olfactory receptor neurons. The neurons’ axons were carried out
as olfactory cilia, which were twisted with the olfactory
bulbs through the cribriform plate. The inability of odor
to reach the olfactory clefts due to infections of the mucous
membranes, in addition to blockage of the nasal cavity. A

study relied on CT of the nasal sinuses to assess the opacity of the olfactory clefts showed that the total opacity was
4.3%, while the partial opacity was 69.6%. No cases displayed ethmoid air cells opacification or nasal cavity opacification [51].
– MRI Assessment: The method of MRI of nerves
was the most appropriate method for anatomical imaging.
Therefore, MRI was used to assess olfactory dysfunction
associated with post-viral infection, neurodegenerative processes, and trauma. Particularly, the coronal T2 weighted
images covering the olfactory bulb anterior pole to the primary olfactory area and conventional sequences for the
whole brain [51]. The quantitative measurements were
achieved through MRI specific to the olfactory nerves for
olfactory bulb volumes, olfactory sulcus depth, qualitative
evaluation of olfactory bulb morphology, signal intensity,
olfactory nerve cilia measurements, and primary olfactory
cortex signal intensity olfactory bulb volumes. The presence of an excessively intense signal in the olfactory bulb
appeared in the form of simple bleeding indicating the presence of inflation. Rarity and clustering were used to assess the olfactory nerve cilia. A multi-planar reconstruction
(MPR) was used to determine the size of the olfactory bulb
[51].
– Olfactory Sulcus Depth: The depth to the olfactory sulcus deepest point could be calculated through coronal T2 weighted images. The relationship between the DTI
scores and the depth of the right olfactory sulcus was negative. There was no relationship between the DTI scores
and the depth of the left olfactory sulcus. There was no relationship between the depth of the sulcus and the sizes of
olfactory bulbs [51].
– Signal Intensity Evaluation: The appearance of
several foci with a very high density in the olfactory bulbs
and the presence of high intensity around these foci. The results of MRI which were collected concerning the pattern of
the shape and the bulb of the signal proved that there was
no statistically meaningful dissimilarity between the sizes
of the olfactory bulbs, the scores of DTI, and the depths of
the olfactory sulcus. The olfactory nerve cilia structure appeared normally, and clusters appeared [51].

3. Treatment Strategies and Follow-Ups
The current section presents some of the treatment
strategies proposed by many researchers that may stop or
reduce the infection of COVID-19. Additionally, it presents
the importance of follow-up for those recovering from
COVID-19, as still many unknown sequelae for those recovered. Therefore, follow-up is necessary for those recovering from COVID-19 to know their clinical needs and discover the unknown long-term sequelae.
3.1 Treatment Strategy of COVID-19
The current subsection presents some of the proposed
therapeutic strategies to confront the COVID-19 virus, in7
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Fig. 5. The treatment strategy summarisation of COVID-19 based on system of renin angiotensin that responsible for adjust high
blood pressure.

cluding the role of ACE2 and AT1-R receptors as therapeutic strategies. Modern treatment strategies played an important role in eliminating or decreasing the incidence of
COVID-19 infection in the heart, lung, and kidney [86].
Seif et al. [86] introduced some strategies for the treatment
of COVID-19. The ACE2, angiotensin II receptor type I obstructor (AT1-R obstructors), restraint of ACE, and peptides
of angiotensin 1–7 were among the strategies considered.
As the ACE2 and AT1-R function critical roles in the improvement of COVID-19, innovative treatment techniques
may help to reduce virus-produced heart, lung, and kidney deterioration. Janus kinase inhibitors (JAKinibs) may
be useful because they may not only lower medical symptoms in the infected many organs, but they may also control
some inflammatory cytokines generated throughout ARDS
or tempest of cytokine [86]. There were two potential treatment strategies for COVID-19, namely (1) ACE2 enzyme
treatment strategy and (2) receptors of ACE2 for treatment
strategy. Fig. 5 summarizes the treatment strategy that will
be examined in detail in the subsequent subsections.
3.1.1 ACE2 Enzyme Treatment Strategy
Angiotensin-converting enzyme-2 is the master key
for SARS-CoVID and COVID-19. The virus attacks the
target cells via the cell protease TMPRSS2. The reninangiotensin system is a very important regulator of blood
pressure, and it is a zinc carboxypeptidase that limits the
activity of the potent vasopressor peptide angiotensin II by
eliminating the terminal residues of phenylalanine to obtain heptapeptide [87]. ACE2 is plentifully available in
the brain, lung, kidney, liver, heart, intestine, and testes
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[88]. The angiotensin-converting enzyme interacts with the
spike protein on the surface of the virus [89]. This interaction leads to activation of the disintegrin, metalloprotease17
(ADAM17) [90]. This reaction results in the elimination of
the ACE2 enzyme present in the target cells, thus, generating greater levels of AngII and hyaluronan that contribute
to the exacerbation of acute respiratory distress syndrome
that leads to death [91].
Therefore, therapeutic strategies based on soluble
ACE2 or ACE2 antibodies can reduce the interaction between COVID-19 and ACE2. Also, according to the administration of soluble receptor-binding domain (RBD), the
basic domain derived from spike protein on the surface of
the virus may prevent the virus from entering cells because
it contains 193 amino acids and it can connect with ACE2
[92].
3.1.2 Receptors of Angiotensin II for Treatment Strategy
AT1-R and AT2-R are two types of G-protein-coupled
receptors through which AngII can function. AT1- R is responsible for the majority of cardiovascular work, while
the adult cardiovascular system contains very little AT2R. There is a proposed treatment for COVID-19 through
angiotensin II receptor blockers (e.g., losartan, valsartan,
telmisartan, and candesartan). A study showed that older
patients who have other comorbidities with COVID-19 and
who were given antihypertensives such as angiotensin receptor blockers are less susceptible to lung injuries [93].
Angiotensin receptor blockers,
angiotensinconverting enzyme inhibitors, Ang (1–7) peptides,
ACE2, and aldosterone synthase inhibitors are all sug-
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Fig. 6. The base phases on diagnosing COVID-19 using AI.

gested strategies that may prevent or limit heart and lung
injuries caused by COVID-19 [94]. Despite this, abrupt
discontinuation of these inhibitors may cause problems
in some patients at high risk in the case of COVID-19
infection [95]. For some people with ARDS, this syndrome
may occur due to the production of excessive levels of
inflammatory cytokines, including IL-1, IL-2, IL-6, IL-7,
IL-10, and TNF-α. Therefore, Janus Kinase is a novel
strategy to control COVID-19, as JAK acts to regulate the
immune system [35].
The plasma of people recovering from COVID-19 infection is considered a treatment strategy for COVID-19.
The plasma of the recovered people can identify the antibodies to the virus. It is preferable to inject patients at an
early stage of infection with plasma from people who have
recovered from COVID-19 [96].
3.2 Follow-Up after Recovering from COVID-19
The current subsection presents the importance of conducting follow-ups with recovering persons from COVID19 to know their clinical needs. Follow-up is carried out in
different ways, e.g., assessments of the body by assessment
of the respiratory system and other assessments for different
organs, through the follow-up stage, the long-term sequelae
of COVID-19 can be detected.
Arnold et al. [97] presented an investigation into
the follow-up phase of COVID-19 patients. The average follow-up period was about 90 days from the onset of
COVID-19 symptoms, and their study included 110 people.
The participants underwent several tests, including spirometry, exercise test, blood tests, and chest radiography. Their
results were as follows: 39% had difficulty breathing, 7%
had normal oxygen levels, 39% had severe fatigue and decreased physical ability, 5 patients had abnormalities on
chest radiography, 12 patients had liver abnormalities, and
9 patients had abnormal kidney function. A decreased lymphocytes were found in 2 of the participants and an increase
in the level of CRP in found 2 of the participants [97].
The consequences of COVID-19 after clinical treatment are still unknown. Therefore, Rovere et al. [98] investigated the consequences of COVID-19 in a follow-up
phase to determine the clinical requirements of those re-

covering from COVID-19. The study included 453 followers, who underwent a multidisciplinary assessment by
conducting several tests, i.e., pulmonary function (physical
examination, blood oxygen level, respiratory rate, and lung
function assessment), cardiovascular assessment, and neurological assessment as well. The results proved that those
recovering from COVID-19 in the follow-up phase still suffer from some symptoms of COVID-19, such as low oxygen levels, which leads to difficulty breathing, decreased
lymphocyte count, and elevated CRP levels [98].

4. Ai-Based Systems for Diagnosing
COVID-19
Artificial intelligence (AI) plays an important role in
diagnosing diseases such as breast cancer [40], liver cancer
[99], renal cancer [100], brain cancer [101], heart failure
[102], and recently COVID-19 [103,104]. It is also possible to utilize AI to detect and anticipate massive epidemics.
The rapid increase in the number of infections has prompted
the use of AI approaches to forecast the likely result of a person infected to provide suitable therapy. Most of the studies
share base phases including data retrieval (i.e., acquisition),
data pre-processing, segmentation, and classification [105].
The phases can be summarized in a framework as shown in
Fig. 6.
4.1 Image Retrieval and Acquisition
The first phase focuses on how the datasets can be retrieved. There are two common paths. The first is getting
the data manually from organizations, hospitals, and clinics. The advantage of this approach is that the researcher
can manage the styles of the obtained cases. However, the
drawbacks are time consumption and potential leakage of
protected health information in annotations [106]. The second path is working on anonymized, shared datasets that
can be available to the public with or without license agreements. It is worth mentioning that, most of the datasets
related to COVID-19 comprise images [107]. Currently,
many COVID-19 datasets are available online on different
platforms such as Kaggle and GitHub. Table 1 (Ref. [108–
110]) summarizes some of these datasets.
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Table 1. The discussed COVID-19 datasets summarization.
Dataset

Link

Type

Size

Classes

https://www.kaggle.com/andyczhao/COVIDxcxr2

X-Ray

16.8K

Positive and
Negative

COVID × CT [109]

https://www.kaggle.com/hgunraj/COVIDxct

CT

195K

Normal, Pneumonia,
and COVID-19

Chest X-ray (COVID-19 and Pneumonia)

https://www.kaggle.com/prashant268/chestxray-COVID19-pneumonia

X-Ray

6.4K

Normal, Pneumonia,
and COVID-19

CT

19.6K

Non-informative,
Positive, and
Negative

COVID × CXR-2 [108]

CT Scans for COVID-19 Classification [110]

https://www.kaggle.com/azaemon/preprocessedct-scans-for-COVID19
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Fig. 7. Summarization of the image pre-processing techniques.

4.2 Image Pre-Processing
The second phase is the pre-processing which focuses
on enhancing the quality of images, balancing the sizes,
and augmenting them. There are different pre-processing
techniques and selecting the sui ones requires deep knowledge and experimental trials [111]. It is proven that the
pre-processing techniques enhance the overall performance
value [112]. Fig. 7 summarizes the image pre-processing
techniques.
4.2.1 Data Resizing
Data or image resizing focuses on changing the dimensions of an image to a target size (i.e., width and
height) [113]. There are multiple resizing techniques such
as nearest-neighbor interpolation, bilinear and bicubic algorithms, and Fourier-transform methods. In addition to
that, there are content-aware resizing methods such as seam
carving [114].
4.2.2 Data Scaling
Scaling techniques are responsible for changing the
scale of the image data range. There are different scaling techniques such as normalization, standardization, minmax, and max-abs scalers [115]. Kand et al. [116] used
normalization and standardization while Ahsan et al. [117]
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used the four mentioned techniques.
4.2.3 Data Balancing
Data balancing techniques target to equalize the number of records in each category (i.e., class). There are two
common approaches. The first is the undersampling while
the second is the oversampling. In the undersampling approach, only some records from the majority class are selected. The number of the selected records is equal to the
number of records in the minority class. On the other hand,
in the oversampling approach, copies from the minority
class are created. The number of the created records is equal
to the number of records in the majority class. Reshi et al.
[118] used one of the data balancing approaches.
4.2.4 Data Augmentation
Data augmentation is useful to increase the diversity
of the images. It can be implemented using generative adversarial networks (GAN) or traditional approaches such as
shifting and shearing. Khalifa et al. [119] used GANs to
augment their COVID-19 dataset. Bao et al. [120] proposed the COVID-GAN to estimate mobility under various real-world conditions. Traditional approaches include
cropping, shifting, shearing, brightness changing, rotation,
and zooming. Monshi et al. [121] used resizing, rota-
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tion, zooming, wrapping, lightening, flipping, and erasing
in their augmentation pipeline.
4.2.5 Enhancement Techniques
There are different image enhancement techniques
such as applying filters, histogram equalization, color conversion (i.e., grayscale conversion and binarization), and
edge detection [122]. David et al. [123] studied the impact
histogram equalization and color mapping in the COVID19 detection task. Siracusano et al. [124] combined the
bidimensional empirical mode decomposition with the contrast limited adaptive histogram equalization (CLAHE) algorithm.
4.3 Image Segmentation
Image segmentation can be categorized concerning
different points of view. The first point of view is the
level of automation that includes three different categories: (1) manual, (2) semi-automatic, and (3) fully automatic. The manual approach requires expert intervention. This approach is time-consuming but effective. The
semi-automatic approach injects computer image processing methods and techniques into its working pipeline. Human interaction is required in the initialization, feedback,
and evaluation processes. Lastly, the fully automatic approach required no human interaction [125]. The second
point of view is the architecture that can be categorized
into classical and machine learning- based techniques. The
machine-learning-based techniques can also be categorized
into traditional, neural network-based, and deep learningbased techniques [126]. Fig. 8 summarizes the image segmentation techniques.
Chakraborty et al. [127] proposed a method named
SuFMoFPA which is used to segment the radiological images. They used the type-2 fuzzy clustering system and
used the super-pixel concept to process the spatial infor-

mation of the CT scan images efficiently. Yan et al. [128]
proposed a deep convolutional neural network to segment
the CT scan images. They reported dice similarity values
of 0.726 and 0.987 for COVID-19 and lung segmentation
respectively. Muller et al. [129] suggested a segmentation model which was based on the standard 3D U-Net.
They reported dice similarity values of 0.761 and 0.956
for COVID-19 and lung segmentation respectively. Abd
Elaziz et al. [130] proposed a method named MPAMFO.
They depended on enhancing the Marine Predators Algorithm (MPA) performance using the moth-flame optimization (MFO) operators. Singh et al. [131] proposed the
FFQOAK (FFQOA + KMC) which is based on the fast
forward quantum optimization algorithm (FFQOA) and Kmeans clustering (KMC) algorithm. Liu et al. [132] suggested the CLACO which is based on the ant colony optimization, the greedy Levy mutation, and the Cauchy mutation. Table 2 (Ref. [127–132]) summarizes the discussed
related studies.
4.4 Image Classification
In the image classification phase, the target model
focuses on selecting the most suitable parameters aiming to reach state-of-the-art performance in the evaluation process. There are different classification algorithms.
They can be categorized into machine learning-based, deep
learning-based, and hybrid learning- based algorithms. In
the machine learning-based category, the algorithm accepts
the features as inputs as it can’t extract them automatically.
Random forest and decision trees are examples. In the deep
learning-based category, the features are extracted automatically and hence the algorithm accepts the raw data as inputs. Lastly, in the hybrid learning-based category, multiple algorithms can be combined sequentially (i.e., multistage) or in parallel [133]. Fig. 9 summarizes the classification categories and techniques.
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Table 2. Summarization of the COVID-19 related studies concerning image segmentation.
Reference
Chakraborty et al. [127]
Yan et al. [128]
Muller et al. [129]
Abd Elaziz et al. [130]
Singh et al. [131]
Liu et al. [132]

Approach

Dataset type

SuFMoFPA with type 2 fuzzy clustering system
Deep convolutional neural network
3D U-Net-based model
MPAMFO
FFQOAK
(FFQOA + KMC) CLACO

CT
CT
CT
CT
CT
X-Ray

Classiﬁcation

Machine Learningbased

Deep Learningbased

Hybrid Learningbased

Naive Bayes

Deep Neural Network

k-Nearest Neighbour

Convolutional Neural
Network

Support Vector
Machines
Decision Trees
Random Forest
Extra Trees

Recurrent Neural
Network
Autoencoder
Boltzmann Machine

Multi-layer Perception
Boosting
Bagging

Ensemble Models

Feature Selection

Feature Reduction

Feature Extraction

Optimization

Fig. 9. Classification categories and techniques taxonomy.

As mentioned, machine-learning-based techniques require the features as inputs, and hence feature selection,
reduction, and extraction can be used. Feature selection
is the process of filtering irrelevant or redundant features
[134]. Feature extraction is the process of creating new features that express useful information. Feature reduction is
the process of combining two or more features into one or
more features where the output features are less than input features [135]. Optimization plays an important role
in the classification process. It can accelerate reaching the
global (or approximate) optimum targets. It can be used to
optimize the parameters (i.e., weights) and hyperparameters (i.e., training configurations). Nadam, Adam, and AdaGrad are examples of the parameter optimizers that can be
used with deep learning while genetic algorithms, Sparrow
search algorithm [136], and Manta-Ray foraging algorithm
[137] are examples of the meta-heuristic optimizers that
can be used in both (i.e., parameters and hyperparameters)
[138,139].
4.5 System Evaluation
The current subsection introduces the performance
metrics that can be used to evaluate artificial intelligencebased systems. Also, they can be used to compare the
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state-of-the-art approaches concerning the segmentation
and classification processes.
4.5.1 Performance Metrics
Sensitivity is the ability to identify diseased patients
correctly. Specificity is the ability to identify non-diseased
people correctly. Precision is a basic measurement for determining the number of patients accurately recognized in
a dataset with an uneven class distribution. The properly
identified patients’ number in an uneven category dataset
among all the patients who may have been foretold is known
as recall. The F1 score achieves the ideal equilibrium of
recall and precision, allowing for a proper assessment of
the model’s execution in categorizing patients with SARSCOV-2. The Dice similarity coefficient is a reproducibility
validation metric and a spatial overlap index that represents
a similarity metric between the ground truth and the prediction score maps [140]. Eqns. 1 to 6 show the mentioned
performance metrics where TP is the true positive, FP is the
false positive, TN is the true negative, and FN is the false
negative.
Accuracy =

TP + TN
TP + TN + FP + FN

(1)

Table 3. Summarization of the COVID-19 related studies concerning classification algorithms.
Reference

Year

Approach

Dataset type

Dataset size

Best performance

Zoabi et al. [142]

2021

Gradient boosting and
decision trees

Numerical records

51,831

0.90 AUC

Kassania et al. [143]

2021

DenseNet121 feature
extractor with Bagging tree
classifier

X-Ray and CT images

137

99% accuracy

Afshar et al. [144]

2021

N/A

CT images and numerical ecords

305

N/A

Khuzani et al. [145]

2021

Multi-layer neural network

X-Ray images

420

94% accuracy

Oh et al. [146]

2020

Probabilistic Grad- CAM

X-Ray images

502

88.9% accuracy

N/A, Not applicable.

Specificity = TNR =

Precision = PPV =

TN
TN + FP

TP
TP + FP

Recall = Sensitivity = TPR =

F1 =

TP
TP + FN

(2)

(3)

(4)

2 × Precision × Recall
Precision + Recall

(5)

2 × TP
2 × TP + FP + FN

(6)

Dice =

4.5.2 State-of-the-Art Systems Comparisons
Kwekha et al. [141] reviewed 14 published articles to investigate the machine learning role and how
it deals with COVID-19. They concluded that supervised learning is better than unsupervised learning as it
had 92.9% testing accuracy. Zoabi et al. [142] created a machine learning-based system that was based on
gradient boosting with decision trees. They trained it
on 51,831 records where 4769 of which were COVID19 cases. They made their data available in English at
https://github.com/nshomron/COVIDpred. They reported
0.90 AUC, 87.30% sensitivity, and 71.98% specificity.
Kassania et al. [143] used the deep learning-based approach
by testing the MobileNet, DenseNet, Xception, ResNet,
InceptionV3, InceptionResNetV2, VGGNet, and NASNet
transfer learning models. They validated their models only
with public X-Ray and CT datasets. They concluded that
the DenseNet121 feature extractor with Bagging tree classifier reported the best performance with 99% accuracy. Afshar et al. [144] collected the COVID-CT-MD dataset that
contained 169 positive, 60 CAP, and 76 normal cases. They

compared their dataset with another 8 datasets.
Khuzani et al. [145] collected 420 X-Ray images and resized them to (512, 512). Their dataset was
grouped into three classes (i.e., COVID-19, pneumonia,
and normal). They used a multi-layer neural network
with two hidden layers and reported 94% accuracy after
33 epochs. They made their work and dataset available
at https://github.com/abzargar/COVID-Classifier.git. Oh et
al. [146] inspired their approach from the statistical analysis of the potential imaging biomarkers of the X-Ray images. They worked on the segmentation and classification
tasks and applied them to public datasets. They proposed
a probabilistic Grad-CAM saliency map that is tailored to
the local patch-based approach. They reported 88.9% and
79.8% classification accuracies with and without masks respectively. Table 3 (Ref. [142–146]) summarizes the discussed related studies. The table is ordered in a descending
order concerning the publication year.

5. Limitations
The limitations of the current survey can be summarized as follows:
– The sample size used by the studies of this survey to
conduct various tests and examinations to confirm the results of infection with COVID-19 infection is rather small.
– Cases of COVID-19-associated anosmia were subjected to medical imaging several months after the onset of
olfactory impairment, so imaging results indicate moderate
changes, not acute or chronic changes.
– Loss of smell and olfactory bulbs still have unclear
changes that need more future studies to explain. So far,
no unified treatment strategy for COVID-19 infection has
been obtained that suits all patients in the world.
– All the proposed strategies are under trial and used
according to the biological nature of the patient’s body and
the response of each patient.
– All of the COVID-19 drugs mentioned in this survey
are still under trial until a drug suitable for all patients and
designated for COVID-19 infection is obtained.
– In general, there is a need for more studies on every13

thing related to COVID-19 in the future to reach accurate
results so that the appropriate treatments for the virus can
be known.

[2]

6. Conclusions and Future Work
In this survey, we reviewed the COVID-19 infection
and its repercussions on many organs such as the lung,
heart, brain, kidney, and other organs. We presented the
symptoms for the short and long-term. We discussed the
impacts of COVID-19 on olfactory bulb and We presented
the reasons for olfactory dysfunction and anosmia related
to COVID-19 by performing various measurements based
on the results of some types of medical imaging in many
different studies. We also reviewed the latest therapeutic
strategies needed to confront COVID-19 infection, such as
the strategy of using ACE2 enzyme and the strategy of using
AngII receptors. We discussed some of the follow-up tests
that have been done for people who have recovered from
COVID-19, through which we can identify the unknown
long-term sequelae of the COVID-19 virus. Finally, we discussed some of the artificial intelligence systems and rules
that are used to predict and diagnose COVID-19. In the future, we hope to arrive at a radical treatment strategy that is
sure and reliable as a direct, safe, and effective treatment for
the COVID-19 virus and strengthen the role of artificial intelligence in forecasting, early detection, diagnosis, as well
as treatment.
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